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Human parainfluenza virus type 3 (HPIV3) is a single-stranded negative-sense RNA virus belonging to the Respirovirus
genus of the Paramyxoviridae family in the order Mononegavirales. The P gene encodes at least four proteins, including the
C protein, which is expressed from an open reading frame (ORF) that overlaps the P ORF, and the D protein, which is encoded
when the P ORF is fused to the D ORF by transcriptional editing. The P mRNA also contains a third ORF for the V protein,
although it is unclear how or whether this ORF is accessed. We have used recombinant DNA technology to recover five
mutant viruses that either interrupt or alter the C, D, and V ORFs. In one mutant virus, rC-KO, expression of the C protein was
abrogated by changing the start codon from methionine to threonine and introducing two stop codons at amino acid positions
7 and 26 of the C ORF. In a second mutant virus, rF164S, a point mutation was introduced into the C ORF changing amino
acid position 164 from phenylalanine (F) to serine (S), which corresponds to the F170S mutation described in the C protein
of Sendai virus (Itoh et al., J. Gen. Virol. 78, 3207–3215). rC-KO was significantly attenuated in vitro and in vivo (rodents and
primates), whereas rF164S was attenuated only in vivo. Interestingly, the rF164S mutant was more attenuated in the upper
than in the lower respiratory tract of hamsters and monkeys. This pattern is the converse of that seen with temperature-
sensitive attenuating mutations, and thus inclusion of this novel mutation in a recombinant live-attenuated vaccine candidate
might prove useful in reducing residual virulence in the upper respiratory tract. Both rC-KO and rF164S conferred protection
against challenge with wild-type HPIV3. In three other viruses, the D and V ORFs were interrupted singly or in combination.
Although interruption of the D and V ORFs individually did not affect virus replication in vitro or in vivo, interruption of
both together attenuated replication in vivo. These results indicate that the C, D, and V proteins of HPIV3 each has a role in
virus replication in vitro, in vivo, or both, and define mutations that might be useful for the development of a vaccine against
HPIV3.
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aINTRODUCTION
Human parainfluenza virus type 3 (HPIV3) is a com-
on cause of serious lower respiratory tract infection in
nfants and children younger than 1 year old. It is second
nly to respiratory syncytial virus (RSV) as a leading
ause of hospitalization for viral lower respiratory tract
isease in this age group (Collins et al., 1996; Crowe,
995; Marx et al., 1997). A vaccine is not currently avail-
ble for the prevention of HPIV3 disease, but there are
wo live attenuated candidate vaccines in clinical trials
Karron et al., 1996, 1995a, 1995b). HPIV3 is a member of
he newly renamed Respirovirus genus of the Paramyxo-
iridae family in the order Mononegavirales. Its genome
s single-stranded, negative-sense RNA of 15462 nucle-
tides (nt). At least eight proteins are encoded by the
enome: the nucleocapsid protein N, the phosphoprotein
, the nonstructural protein C, the D protein, the matrix
rotein M, the fusion glycoprotein F, the hemagglutinin-
euraminidase protein HN, and the large polymerase
rotein L (Collins et al., 1996). The HPIV3 genes are each
1 To whom reprint requests should be addressed at 7 Center Dr.,
KSC 0720, Bethesda, MD. Fax: (301) 496-8312. E-mail: adurbin@nih.gov.
319ranscribed as a single mRNA that encodes a single
rotein, with the exception of the P mRNA, which con-
ains four open reading frames (ORFs), namely P, C, D,
nd V (Fig. 1) (Galinski et al., 1992; Spriggs and Collins,
986).
The P and C proteins are translated from separate,
verlapping ORFs in the mRNA (Fig. 1). Although all
aramyxoviruses encode a P protein, only members of
enus Respirovirus or Morbillivirus encode a C protein.
ndividual viruses vary in the number of proteins ex-
ressed from the C ORF and in its importance in repli-
ation of the virus in vitro and in vivo. Sendai virus (SeV)
xpresses four independently initiated proteins from the
ORF: C9, C, Y1, and Y2, whose translational start sites
ppear in that order in the mRNA (Curran and Kolakofsky,
990; Lamb and Paterson, 1991), whereas HPIV3 and
easles virus (MV) express only a single C protein
Bellini et al., 1985; Sanchez and Banerjee, 1985; Spriggs
nd Collins, 1986). Recombinant DNA technology has
ade possible the recovery of infectious negative-
tranded RNA viruses from cDNA (Baron and Barrett,
997; Collins et al., 1995; Durbin et al., 1997a; Garcin et
l., 1995; He et al., 1997; Hoffman and Banerjee, 1997;
ato et al., 1996; Radecke et al., 1995; Schnell et al., 1994;
0042-6822/99
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320 DURBIN ET AL.FIG. 1. Organization of the HPIV3 P, C, D, and V ORFs (not to scale). The three reading frames of the P mRNA are shown (11, 12, and 13) with
he P, C, D, and V ORFs represented by rectangles. Amino acid lengths are indicated. The position of the RNA editing site is shown as a vertical line,
nd its sequence motif is shown and numbered according to its nucleotide position in the complete HPIV3 antigenomic sequence. (A) Organization
f the unedited P mRNA. The sequence containing the translational start sites of the P and C ORFs is shown and is numbered according to the
omplete antigenomic sequence. The nucleotide positions of the P, C, D, and V ORFs in the complete antigenomic sequence are P, 1784–3595; C,
794–2393; D, 2442–2903; and V, 2792–3066. Relative to the P mRNA, the AUG that opens the P ORF is at positions 80–82. (B) Organization of an edited
ersion of the P mRNA that contains an insertion of two nontemplated G residues (GG) in the editing site. This changes the reading register so that
he upstream end of the P ORF in frame 12 is fused to the D ORF in frame 13. The resulting chimeric protein contains the N-terminal 241 amino
cids encoded by the P ORF fused to the C-terminal 131 amino acids encoded by the D ORF. (C) Positions of mutations that alter or ablate the C, D,
nd V ORFs, illustrated on the edited version of the P mRNA from B. Introduced stop codons are indicated by vertical lines within rectangles. The
ORF was modified (1) to change codon 1 from M to T and codons 7 and 26 to create stop codons or (2) to change codon 164 from F to S. The D
RF was modified to introduce stop codons at codons 304, 305, and 306, numbered according to the 372-amino-acid chimeric D protein containing
he N-terminal 241 amino acids of P fused to the C-terminal 131 amino acids of the D. The V ORF was modified to introduce stop codons at codons
7 and 20. These latter two mutations resulted in amino acid substitutions at codons 354 and 357 of the D ORF (asterisks).
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321C, D, AND V ORF MUTATIONS OF HPIV3helan et al., 1995), including recombinant viruses with
utations in C. A viable recombinant SeV in which all
our C-derived proteins were ablated replicated ex-
remely inefficiently in vitro (Kurotani et al., 1998),
hereas ablation of individual C proteins had complex
ffects (see Discussion) (Cadd et al., 1996; Curran et al.,
992; Latorre et al., 1998). A recombinant SeV bearing a
ingle point mutation resulting in a phenylalanine (F)-to-
erine (S) substitution at amino acid position 170 of the C
rotein was attenuated in mice, but its replication in cell
ulture was not impaired (Garcin et al., 1997; Itoh et al.,
997). In marked contrast to SeV, a C-minus MV repli-
ated efficiently in Vero cells (Radecke and Billeter,
996), although it exhibited restriction of replication in
uman peripheral blood cells and appeared to be some-
hat attenuated in vivo (Escoffier et al., 1999; Valsamakis
t al., 1998).
In addition to the P and C ORFs, the P mRNA of PIV3
as two other ORFs, namely, D and V. The PIV3 D protein,
fusion protein of the P and D ORFs, is expressed from
he P gene by the process of transcriptional editing in
hich two nontemplated G residues are added to the P
RNA at the RNA editing site (Fig. 1) (Galinski et al.,
992; Pelet et al., 1991). BPIV3 is the only other
aramyxovirus that expresses a D protein, and it does so
ia the same mechanism. The paramyxovirus V protein
lso is expressed by RNA editing, which fuses the up-
tream end of the P ORF to a downstream ORF that
ncodes the high-conserved cysteine-rich V domain
Cattaneo et al., 1989; Curran et al., 1991; Park and
rystal, 1992; Spriggs and Collins, 1986; Thomas et al.,
988; Vidal et al., 1990). Nearly all members of the genus
espirovirus, Rubulavirus, or Morbillivirus express a V
rotein. The one member that clearly does not is HPIV1,
hich lacks an intact V ORF (Matsuoka et al., 1991).
PIV3 expresses a V protein by the addition of a single
ontemplated G residue at the editing site. However, in
he case of HPIV3, two translation stop codons lie be-
ween the editing site and the V ORF, and it is not clear
hether HPIV3 represents another example in which this
RF is not expressed or whether it is expressed by some
ther mechanism. One possibility is that HPIV3 editing
lso occurs at a second, downstream site in the P gene,
lthough this did not appear to occur in cell culture (Galin-
ki et al., 1992). Alternatively, it might be that ribosomes gain
ccess to the V ORF through ribosomal frameshifting. This
ould be comparable to the situation with the P locus of
V. MV expresses C, P, and V proteins but also expresses
novel R protein that is synthesized by frameshifting from
he P ORF to the V ORF (Liston and Briedis, 1995). Although
he means by which HPIV3 expresses its V protein is
nclear, the extreme conservation of the V ORF in different
trains suggests that it is indeed expressed. The function of
he V protein is not well defined, but V-minus MV and SeV
ecombinants have been recovered that replicate efficiently sn vitro but exhibit reduced replication in vivo (Delenda et
l., 1997, 1998; Kato et al., 1997a,b; Valsamakis et al., 1998).
The altered replication of the various MV and SeV C
nd V mutants in animals suggested that these ORFs
ould be reasonable and interesting targets for produc-
ion of attenuating mutations that might be useful in the
evelopment of a live attenuated HPIV3 vaccine. We
reviously recovered infectious HPIV3 [JS wild-type (WT)
train] from full-length cDNA and demonstrated that the
ecombinant virus was phenotypically identical to its
iologically derived parent virus (Durbin et al., 1997a). In
he present report, we used this recombinant cDNA sys-
em to introduce mutations into the C ORF that either
ompletely silenced its expression or created an F to S
hange at amino acid position 164, which corresponds to
he F to S change at amino acid position 170 in the
ttenuated SeV mutant. We also introduced stop codon
utations into the D and V ORFs, which should silence
xpression of these proteins by the virus. We describe
he effects of these mutations on viral replication and
athogenesis and discuss their role in the development
f a live attenuated viral vaccine for the prevention of
PIV3 disease.
RESULTS
ecovery of recombinant mutants rC-KO, rD-KO,
V-KO, rDV-KO, and rF164S
HPIV3 antigenomic cDNAs were prepared to encode
he following five mutant viruses (Table 1, Fig. 1): (1)
C-KO, in which the C ORF was modified to change the
nitiating codon from M to T and introduce translational
tops at codons 7 and 26; (2) rF164S, in which C codon
64 was changed from F to S; (3) rD-KO, in which trans-
ational stops were introduced at codons 304, 305, and
06 in the 372-amino-acid chimeric D protein; (4) rV-KO,
n which stop codons were introduced at positions 17
nd 20 in the V ORF; and (5) rDV-KO, in which the
utations in 3 and 4 were combined. Each mutation was
ranslationally silent in the overlapping ORFs except in
he case of the two stop codons introduced into the V
RF (4), which resulted in two amino acid substitutions
n D, namely Q354L and A357V, that could not be
voided. Furthermore, the stop codons in D were not
ntroduced earlier in the ORF because they would have
ltered P. Each mutation was introduced together with a
ranslationally silent restriction site marker except for C
164S (Table 1).
The antigenomic cDNAs were transfected into HEp-2
ells along with the three PIV3 support plasmids [pTM (P
o C), pTM (N), pTM (L)], and the cells were simulta-
eously infected with recombinant modified vaccinia
train Ankara (MVA) expressing the T7 RNA polymerase.
he efficiency of recovery of rPIV3 containing the muta-
ions in the C, D, or V ORFs was compared with that of a
imilarly transfected-infected HEp-2 cell culture using
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322 DURBIN ET AL.3/7(131)2G, the plasmid expressing full-length PIV3 an-
igenome from which recombinant JS WT PIV3 (rJS) was
reviously recovered (Durbin et al., 1997a). After incuba-
ion for 3 days at 32°C, the transfected cells were har-
ested, and each supernatant was passaged onto a
resh monolayer of LLC-MK2 cells in a T25 flask and
ncubated for 5 days at 32°C (passage 1). After 5 days at
2°C, the LLC-MK2 cell monolayer of rJS, rF164S, rD-KO,
V-KO, and rDV-KO exhibited 13 or 14 cytopathic effect
CPE). The corresponding passage 1 of rC-KO exhibited
inimal, if any, CPE. Because it was unclear whether the
ack of CPE in the rC-KO sample was due to a high level
f growth restriction of the mutant virus or simply due to
ery low initial recovery of virus, passage 1 was har-
ested, and the supernatant was passaged onto a fresh
onolayer of LLC-MK2 cells in a T75 flask and incubated
or 7 days at 32°C (passage 2). The T75 monolayer of
LC-MK2 cells exhibited only 11 or 12 CPE after 7 days
f incubation, but the presence of HPIV3 was confirmed
ia hemadsorption. After three rounds of biological clon-
ng through plaque isolation or terminal dilution, each
ecombinant mutant was amplified twice in LLC-MK2
ells to produce a suspension of virus for further char-
cterization.
To confirm that the recovered viruses indeed were the
xpected rC-KO, rF164S, rD-KO, rV-KO, and rDV-KO mu-
ants, each cloned virus was analyzed by RT-PCR using
primer pair that amplified a fragment of DNA spanning
t 1595–3104 of the HPIV3 antigenome, which includes
he portion of the P gene containing the C, D, and V
RFs. The generation of each PCR product was depen-
ent on the inclusion of RT, indicating that each was
erived from RNA and not from contaminating cDNA
T
Nucleotide Changes Introduced into rPIV3 to Yi
rPIV3 designation
Amino acid
substitution Nucleoti
C-KO, mutation 1 Met1 to Thr 1794-ATG CT
Ser7 to stop ACG CT
C-KO, mutation 2 Ser26 to stop 1859-CCT CG
CCA GC
F164S Phe164 to Ser 2277-CAA AT
CAA AT
D-KO Ser304 to stopc 2676-CCT CA
Ser305 to stop CGA GC
Ser306 to stop
V-KO Arg355 to stop 2830-GGA AA
Gln358 to stop GGA GC
a The mutations described for rD-KO and rV-KO were combined to c
b The nucleotide sequence of each mutated region is shown and co
s numbered according to its position in the complete antigenome RNA
ntroduced restriction enzyme site. Underlined sequence indicates an
c Numbered according to the sequence of the D fusion protein comb
cids of D (Fig. 1B).data not shown). The PCR product of rC-KO, rD-KO, eV-KO, and rDV-KO was then digested with restriction
nzymes introduced as markers (Table 1), and the pres-
nce of the restriction enzyme sites was confirmed (data
ot shown). Nucleotide sequencing was also done on
he RT-PCR products to confirm the presence of the
ntroduced mutations. All of the introduced mutations
ere confirmed to be present in the RT-PCR fragment
panning nt 1595–3104 amplified from each cloned re-
ombinant, and other incidental mutations were not
ound in this fragment.
To confirm that the C ORF had indeed been silenced,
adioimmunoprecipitation assays (RIPAs) were per-
ormed to compare the rC-KO and rF164S mutant viruses
ith the rJS WT virus. Cells were infected, incubated in
he presence of 35S methionine at 24–30 h postinfection,
nd cell lysates were prepared. The cell lysates contain-
ng total protein were incubated with anti-C and anti-HN
ntibodies, and the antibody was then bound to protein
-Sepharose beads. rJS and rF164S each encoded both
N and C proteins, whereas rC-KO failed to express the
protein (Fig. 2). The C protein expressed by rF164S
ppeared to be of identical size as that expressed by the
arent rJS and was expressed in similar quantity as well
Fig. 2).
eplication of rC-KO, rF164S, and rDV-KO
n cell culture
Duplicate cultures of LLC-MK2 cell monolayers were
nfected with rC-KO, rF164S, rDV-KO, or rJS at an multi-
licity of infection (m.o.i.) of 0.01 and incubated for 7 days
t 32°C. Medium from each culture was sampled at 24-h
ntervals, and this material was subsequently titered to
KO, rF164S, rD-KO, rV-KO, and rDV-KOa Viruses
uence of WT/mutated sequenceb
Restriction enzyme
site introduced
ACT ATC AAA TCA TGG PfIMI
ACT ACC AAA TAA TGG
TCA ACA TCA TTG BssHII
TAA ACA TCA TTG
CAA GCG AGA TAT CAG None
CAA GCG AGA TAT CAG
GGA ATC TCA TCA TCG ACA AC SacI
GGA ATC TAA TAA TAG ACA AC
GGA TAC AGA AGA GAG CAA TCG BsrBI
GGA TAC TGA AGA GAG TAA TCG
e rDV-KO virus.
with wild-type (WT) sequence. The first nucleotide in each sequence
equence indicates introduced mutations, italic sequence indicates the
ced stop codon.
he N-terminal 241 amino acids of P fused to the C-terminal 131 aminoABLE 1
eld rC-
de seq
A AAA
A AAA
G CCC
G CGC
G TTC
G TCC
T CAT
T CAT
G GAA
G GAA
reate th
mpared
. Bold s
introdu
ining tvaluate the replication of each virus in cell culture. The
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323C, D, AND V ORF MUTATIONS OF HPIV3eplication of rD-KO and rV-KO in cell culture was eval-
ated in earlier experiments and found to be no different
rom that of rJS (data not shown). Replication of rF164S
nd rDV-KO was essentially indistinguishable from that
f the parent rJS WT with regard to both the rate of virus
roduction and the peak titer (Fig. 3). In contrast, the
C-KO virus replicated more slowly and reached a peak
iter on day 6 that was 100-fold lower than that of rF164S,
DV-KO, and rJS. Thus the lack of expression of the C
rotein had a significant effect on virus replication in cell
ulture. None of the viruses displayed a temperature-
ensitive phenotype in cell culture (data not shown).
eplication of rC-KO, rF164S, rD-KO, rV-KO, and
DV-KO in hamsters
We then compared the mutant viruses and the rJS WT
arent for the ability to replicate in the upper and lower
espiratory tracts of hamsters. A preliminary study
howed that the rD-KO and rV-KO viruses were indistin-
uishable from the rJS virus in this assay (data not
hown), and they were excluded from further evaluation.
n a second study, groups of hamsters were inoculated
ntranasally with 105 PFU/animal of rC-KO, rF164S, rDV-
O, rJS, or cp45, the biologically derived vaccine candi-
ate. Compared with rJS, replication of rC-KO was re-
uced $1000-fold in both the upper and lower respira-
ory tracts of the hamsters on each day tested (Table 2)
nd was more attenuated than the cp45 vaccine candi-
ate virus. Replication of rF164S was reduced 100- to
FIG. 2. RIPA demonstrating that expression of the C protein has been
brogated in the virus rC-KO but not rF164S. Lane a, cell lysates were
mmunoprecipitated by a mixture of two monoclonal antibodies specific
o the HPIV3 HN protein. The 64-kDa band corresponding to the HN
rotein (filled arrow) is present in all three virus lysates, confirming they
re indeed HPIV3 and express similar levels of proteins. Lane b,
5S-labeled cell lysates were immunoprecipitated with a polyclonal
-specific rabbit antiserum. A 22-kDa band corresponding to the C
rotein (open arrow) is clearly present in rJS and rF164S lysates but
bsent from lane b of rC-KO.00-fold in upper respiratory tract and was reduced .10- lold in the lower respiratory tract of the hamsters. Al-
hough the replication of rDV-KO was not reduced in the
pper respiratory tract of the hamsters, it was reduced
20-fold in the lower respiratory tract (Table 2) on each
f the 3 days tested. The hamsters that were infected
ith rC-KO, rF164S, rDV-KO, cp45, or rJS had a significant
ntibody response to HPIV3 and exhibited a high level of
estriction of replication of PIV3 challenge virus (Table 3).
he protection afforded by rC-KO in the upper respiratory
ract was incomplete but still substantial.
eplication of rC-KO, rF164S, and rDV-KO in primates
To further evaluate the attenuation phenotype and pro-
ective efficacy of rC-KO, rF164S, and rDV-KO, these mu-
ants were each administered to a group of four African
reen monkeys (AGMs), and their replication in the up-
er and lower respiratory tracts was compared with that
f cp45 and JS WT. Replication of rC-KO and rF164S was
100-fold reduced in the upper respiratory tract of the
GMs, whereas rDV-KO was 10-fold reduced at this site.
he attenuation observed for these three viruses in the
pper respiratory tract was comparable to that of cp45
Table 4). Although rC-KO was highly attenuated (.105-
old) in the lower respiratory tract of the AGMs, rF164S
nd rDV-KO were only modestly (,10-fold) restricted at
his site. All three viruses induced an HAI antibody re-
ponse to HPIV3, although the HAI response of AGMs to
C-KO, like that of hamsters, was significantly less than
hat of the other viruses (Table 4). The F164S mutation
emained unaltered in each of eight isolates obtained
ate in the course of virus replication from the four AGMs
nfected with rF164S. The immunized AGMs were chal-
enged on day 28 with 106 PFU of biologically derived JS
T virus administered intranasally and intratracheally.
he animals that had received rJS, rF164S, rDV-KO, or the
p45 vaccine candidate virus were completely protected
gainst replication of challenge virus in both the upper
nd lower respiratory tracts of the AGMs. The protection
FIG. 3. Multicycle replication of the three mutated viruses rC-KO,
F164S, and rDV-KO compared with the parent virus rJS. The virus titers
re shown as TCID50/ml and are the average of duplicate samples. Theower limit of detection of this assay is 10 TCID50.
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324 DURBIN ET AL.onferred by rC-KO against replication of challenge virus
as substantial although not complete. Peak titers of
hallenge virus were significantly reduced in both the
pper and lower respiratory tracts of animals in this
roup (Table 4), and the duration of shedding of virus
rom the upper and lower respiratory tracts was reduced
rom 9 days (JS WT) to 4 days (rC-KO) and from 8 days (JS
T) to 4.5 days (rC-KO), respectively (data not shown).
DISCUSSION
Our success in recovering infectious HPIV3 from
DNA has allowed us to investigate the importance of
he accessory C, D, and V ORFs of HPIV3 to virus repli-
ation in vitro and in vivo. This was evaluated with vi-
uses in which (1) the C, D, or V ORF was individually
T
The rC-KO and rF164 Viruses Are Attenuated in the Upper
Is Attenuated in the Lowe
Virusa
Mean virus titer on indicated day postinfection
Day 3 Day 4
Nasal turb.c Lungs Nasal turb. Lungs
p45 4.7 6 0.2 2.7 6 0.2 5.0 6 0.5 2.8 6 0
C-KO 3.4 6 0.2 2.9 6 0.1 3.6 6 0.1 2.1 6 0
F164S 4.0 6 0.2 5.3 6 0.3 4.7 6 0.3 5.4 6 0
DV-KO 7.2 6 0.2 5.5 6 0.3 6.9 6 0.2 4.6 6 0
JS 6.7 6 0.3 6.8 6 0.5 7.4 6 0.2 6.6 6 0
a Groups of five hamsters were inoculated intranasally with 105 PFU
ecombinant viruses.
b Standard error.
c turb. 5 turbinates.
d Mean values in each column with a different uppercase letter are si
ith the same uppercase letter are not significantly different.
TABLE 3
The rC-KO, rF164S, and rDV-KO Viruses Are Immunogenic and
Protective against Challenge with PIV3 WT Virus in Hamsters
Immunizing
virusa
Serum HAI antibody
titer (reciprocal
mean log2 6 S.E.)
Response to challenge:
Mean PIV3 titerb
(log10 TCID50/g 6 S.E.)
Nasal turb. Lungs
rC-KO 7.3 6 0.4 3.3 6 0.5 ,1.2 6 0.0
rF164S 10.8 6 0.2 ,1.5 6 0.0 ,1.2 6 0.0
rDV-KO 11.3 6 0.2 ,1.5 6 0.0 ,1.2 6 0.0
cp45 11.8 6 0.3 ,1.5 6 0.0 ,1.2 6 0.0
rJS 12.1 6 0.2 ,1.5 6 0.0 ,1.2 6 0.0
RSV ,2.0 6 0.0 7.0 6 0.2 4.7 6 0.3
a Indicates virus used to immunize groups of six hamsters on day 0.
b On day 28, all hamsters were bled to determine the serum HAI
ntibody titer and were challenged with 106 PFU of biologically
erived JS WT HPIV3. Lungs and nasal turbinates were harvested onfay 4 postchallenge.nterrupted by the introduction of translational stop
odons, (2) the D and V ORFs were interrupted together,
r (3) the C protein was modified by a point mutation.
We were able to recover an HPIV3 mutant (rC-KO) that
as unable to express its C protein but was still repli-
ation competent both in vitro and in vivo, confirming that
he C protein of HPIV3, like that of both MV and SeV, is
ot essential for virus replication (Escoffier et al., 1999;
urotani et al., 1998). The effect of abrogating C protein
xpression on replication in vitro varied considerably
mong these three viruses. MV was least affected by
oss of C function. Measles C-minus virus replicated in
ell culture as efficiently as its tissue culture adapted
dmonston B virus parent but was restricted in replica-
ion in human peripheral blood mononuclear cells in vitro
Escoffier et al., 1999; Radecke and Billeter, 1996). How-
ver, the recombinant MV was prepared from the cell
ulture-adapted Edmonston strain. Because adaptation
f MV to cell culture might be associated with one or
ore amino acid changes in the C protein (Takeda et al.,
998), C protein function might already have been com-
romised in the recombinant parent, obscuring the full
ffect of completely ablating its expression. Silencing the
xpression of the C9 and C proteins of SeV resulted in a
02-fold reduction in peak titer achieved during replica-
ion in cell culture, whereas loss of all four proteins
oded by the C ORF, namely, C9, C, Y1, and Y2, resulted
n a 104-fold decrease in viral replication in vitro (Kurotani
t al., 1998; Latorre et al., 1998). The effect of loss of the
protein on replication of HPIV3 in vitro was intermedi-
te between that of MV and SeV. rC-KO achieved a peak
iter after multicycle replication that was 100-fold less
han that of WT HPIV3, and its plaque size was also
iminished. Thus although the C proteins of these
aramyxoviruses are nonessential, they are required for
wer Respiratory Tracts of Hamsters, and the rDV-KO Virus
ratory Tract of Hamsters
CID50/g 6 S.E.)
b
Peak virus titer
(log10 TCID50/g 6 S.E.)
bDay 5
Nasal turb. Lungs Nasal turb. Lungs
5.4 6 0.3 1.6 6 0.2 5.4 6 0.3 (D)d 2.8 6 0.5 (C)d
2.9 6 0.4 1.6 6 0.2 3.6 6 0.1 (C) 2.9 6 0.1 (C)
4.4 6 0.6 4.3 6 0.1 4.7 6 0.3 (B) 5.4 6 0.2 (B)
5.4 6 0.1 5.9 6 0.2 7.2 6 0.2 (A) 5.9 6 0.2 (B)
6.6 6 0.2 7.2 6 0.2 7.4 6 0.2 (A) 7.2 6 0.2 (A)
icated virus. cp45 is a biologically derived virus, and the others are
tly different (a 5 0.05) by Duncan’s multiple range test, whereas thoseABLE 2
and Lo
r Respi
(log10 T
.5
.3
.2
.1
.4
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325C, D, AND V ORF MUTATIONS OF HPIV3The role of the C protein also has been investigated in
ivo. The replication of the C-minus MV recombinant was
educed only 10-fold in mice bearing human thymus/liver
mplants, and its pathogenicity for the human implant
issues appeared to be undiminished (Valsamakis et al.,
998). Evaluation in a more permissive host has not yet
een reported. SeV encodes four proteins from the C
RF, namely C9, C, Y1, and Y2 (whose translational start
ites appear in that order in the mRNA), and the loss of
hese various species has complex effects. Loss of ex-
ression of C alone significantly reduced virus replica-
ion in the lungs of mice, and the virus was essentially
virulent (Latorre et al., 1998). In contrast, a virus in which
xpression of C9 alone was ablated remained fully viru-
ent (Latorre et al., 1998). An rSeV in which expression of
ll four proteins was ablated was so critically impaired
hat pathogenicity studies in mice could not be done
Kurotani et al., 1998). An rSeV in which C9 and C were
ilenced together was .1000-fold restricted in the lungs
f mice and exhibited a pattern of replication in which the
iter peaked 1 day after inoculation and diminished rap-
dly thereafter (Kurotani et al., 1998). Similar to the SeV
9/C knockout, the HPIV3 rC-KO virus was reduced
1000-fold in its replication in the upper and lower
espiratory tracts of hamsters and was highly restricted
n the upper and lower respiratory tracts of AGMs. Unlike
he SeV C9/C knockout, replication of the HPIV3 rC-KO
irus in the upper and lower respiratory tracts of AGMs
radually increased and peaked on days 4 and 5, re-
pectively (not shown). The level of replication of rC-KO
n the upper and lower respiratory tracts of AGMs was
lightly below that of cp45, the most promising PIV3
T
rC-KO, rF164S, and rDV-KO Are Attenuated and Induce
Virusa
Mean peak titer
(log10 TCID50/ml 6 S.E.)
b
No. o
anima
Nasopharyngeal
swab
Tracheal
lavage
C-KO 3.6 6 0.3 (C)e 1.5 6 0.1 (D)e 4
F164S 4.3 6 0.3 (C) 5.8 6 0.2 (B) 4
p45 5.1 6 0.4 (B) 5.3 6 0.1 (C) 4
DV-KO 5.3 6 0.2 (B) 6.0 6 0.4 (B) 4
Swt 6.3 6 0.2 (A) 6.6 6 0.1 (A) 6 f
a AGMs were inoculated intranasally and intratracheally with 106 PF
b Standard error.
c The mean serum HAI antibody titer (reciprocal mean log2) on day
d Animals were challenged on day 28 with 106 PFU HPIV3 JS WT vir
e Mean values in each column with a different letter are significantly
ame letter are not significantly different.
f Two animals in this group received the recombinant JS WT virus rJS,
f the two viruses was not different (6.4 versus 6.3 in the upper respira
iters were not different, the groups were combined for further analyse
g Compare with mean peak titer of JS WT virus in columns 2 and 3.accine candidate strain. Despite its reduced replication Fn vivo, rC-KO was able to induce a sufficient immune
esponse to restrict replication of HPIV3 challenge virus,
uggesting that it might be an efficacious vaccine can-
idate, although it may need to be given at a higher dose
r in multiple doses to humans to achieve a higher level
f restriction of replication of WT virus.
The F170S mutation occurred during adaptation of SeV
o growth in LLC-MK2 simian cells (Garcin et al., 1997;
toh et al., 1997). Although recombinant SeV with the
170S mutation demonstrated enhanced replication in
itro, this mutant was highly restricted in replication in
ice, being as impaired in replication as the SeV C9/C
utant (Garcin et al., 1997; Latorre et al., 1998). Because
he C proteins of SeV and HPIV3 are only 38% homolo-
ous, it was surprising to find that importation of the
170S mutation of SeV into HPIV3 caused attenuation in
ivo. The HPIV3 recombinant rF164S, which bears the
utation at the amino acid residue of HPIV3 analogous
o amino acid 170 of SeV, was not restricted in replication
n vitro, but it was significantly attenuated in both the
pper and lower respiratory tracts of hamsters and
GMs. Although rF164S was attenuated in vivo in ham-
ters and monkeys, its level of attenuation was consid-
rably less than that of the recombinant SeV bearing the
170S mutation. This indicates that the phenotypes spec-
fied by the mutation differed significantly in HPIV3 and
eV, perhaps because the HPIV3 mutant has not been
tudied in its fully permissive, natural host. rF164S in-
uced a serum antibody response comparable to that of
T PIV3 infection and completely protected both ham-
ters and AGMs against challenge with WT HPIV3.
hese results are promising because they identify the
m HAI Antibody Response in African Green Monkeys
Serum HAI
antibody titer on
day 28 (reciprocal
mean log2 6 S.E.)
c
Mean peak titer (log10 TCID50/ml 6
S.E.) of challenge virusd
Nasopharyngeal
swab
Tracheal
lavage
9.2 6 1.1 4.2 6 0.4g 3.6 6 1.0g
12.5 6 0.3 ,0.5 6 0.0 ,0.5 6 0.0
12.0 6 0.6 ,0.5 6 0.0 ,0.5 6 0.0
12.0 6 0.6 ,0.5 6 0.0 ,0.5 6 0.0
13.2 6 0.2 ,0.5 6 0.0 ,0.5 6 0.0
dicated virus on day 0.
#2.0.
n intranasally and intratracheally.
nt (a 5 0.05) by Duncan’s multiple range test, whereas those with the
r animals received the biologically derived JSwt virus. Peak mean titers
ct and 6.6 versus 6.7 in the lower respiratory tract). Because the peakABLE 4
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326 DURBIN ET AL.ive (ts) attenuating mutation that might prove useful in
ur attempts to develop a live attenuated vaccine against
PIV3. Interestingly, this simple missense mutation re-
ained stable after replication in the upper and lower
espiratory tracts of four AGMs.
Using recombinant DNA technology, mutations identi-
ied in cp45 have been introduced singly and in combi-
ation into the JS WT sequence (Skiadopoulos et al.,
999). This has allowed us to identify the mutations that
ontribute to the attenuation, ts, and/or cold-adapted
henotypes of this vaccine candidate. The F164S muta-
ion might be a useful adjunctive non-ts mutation that
ould be added to cp45, if ongoing clinical trials indicate
hat further attenuation is needed, or to other vaccine
andidates to increase their level of attenuation, espe-
ially for the upper respiratory tract. The F164S mutation
s unusual in that it specifies a restriction of replication
hat is greater in the upper respiratory tract than in the
ower respiratory tract. Because human parainfluenza
iruses cause significant disease in the upper respira-
ory tract, including otitis media (Heikkinen et al., 1999),
ttenuation of replication of WT HPIV3 for the upper
espiratory tract represents a desirable phenotype.
The two other proteins that potentially are encoded
ithin the P locus are the V and D proteins. With the
xception of HPIV-1, all respiroviruses, morbilliviruses,
nd rubulaviruses contain an intact V ORF. The cysteine-
ich C-terminal portion of the V ORF is the most con-
erved ORF of the P gene in Paramyxoviridae and ap-
ears to be expressed by all these viruses except HPIV1
nd HPIV3. Although HPIV3 contains the V ORF, it is
nclear how it is accessed, but the fact that it has
emained intact suggests that it is used. Recombinant
eV or MV bearing a mutation or mutations that de-
rease or ablate expression of the V ORF attenuates the
irus in vivo but does not impair replication in vitro
Delenda et al., 1998; Kato et al., 1997a,b; Valsamakis et
l., 1998). The mechanism responsible for impaired rep-
ication in vivo is not known. In our studies, recombinant
PIV3 containing two stop codons introduced within the
irst 20 amino acids of the V ORF was not significantly
estricted in replication in vitro or in vivo.
Unlike the V cistron of the Paramyxoviridae, the D
rotein is unique to human and bovine PIV3. The D
rotein is accessed by insertion of two nontemplated G
esidues at the editing site of the P mRNA, resulting in a
usion protein in which the N-terminal 241 amino acids of
are fused with the C-terminal 131 amino acids of the D
RF. Nothing is known about the function of the D pro-
ein, and it has not yet been identified in HPIV3-infected
ells or virions. In an attempt to address this issue, we
ecovered a recombinant HPIV3 mutant that contained
hree successive stop codons in the D ORF that would
xpress a truncated fusion protein containing 61 amino
cids encoded by the D ORF. This mutant also was not
ignificantly restricted in replication in vitro or in vivo. It mas unclear whether replication was unaffected be-
ause the D protein is nonessential for normal replica-
ion or because the truncated D protein was fully func-
ional.
An additional effort to identify a possible role for the V
nd D proteins in HPIV3 replication was made by com-
ining the two sets of mutations to create a recombinant
PIV3 with stop codons in both the V and D ORFs
rDV-KO). In contrast to the absence of significant effects
bserved with either rD-KO or rV-KO, rDV-KO was re-
tricted in its replication in the lower respiratory tract of
amsters as well as in both the upper and lower respi-
atory tract of AGMs. Because the P ORF was unaffected
y the introduced mutations, it is reasonable to assume
hat the phenotypes we observed reflect the loss of V
nd D activity. Although replication of rDV-KO was atten-
ated in vivo, replication in cell culture was essentially
nchanged. This is not necessarily surprising because
eplication of both the V-minus mutants of SeV and MV
as unchanged in vitro yet significantly attenuated in
ivo. These mutants exhibited less virulence in vivo as
ell, suggesting the V protein may play a role in viral
athogenesis. This provides compelling evidence, albeit
ndirect, that the D and V proteins of WT HPIV3 are
xpressed and that functional abrogation of both to-
ether is responsible for the in vivo attenuation pheno-
ype demonstrated by rDV-KO. It is possible that while
ltering either D or V protein expression individually has
ittle discernible effect on viral replication, alteration of
he expression of both proteins amplifies this effect to
uch an extent it can then be observed. Whether these
roteins are interacting with one another on a molecular
evel to affect in vivo replication of HPIV3 is also unclear.
he D and V ORFs have no significant amino acid se-
uence similarities apart from the likelihood that V, like
, contains N-terminal amino acids of P. Closer analysis
f the bovine D and V proteins may provide some insight
nto any possible interactive relationship of the two pro-
eins.
We have used reverse genetics to generate several
utations in the C, D, and V ORFs of HPIV3 that might be
seful for the development of a live attenuated vaccine
or the prevention of HPIV3 infection and disease. rC-KO,
lthough highly attenuated, induces a significant protec-
ive effect, and this is an efficacious vaccine candidate
n its own. Because the F164S and DV-KO mutations
pecify a lower level of attenuation compared with that of
p45, they would be primarily useful as adjunctive mu-
ations to further attenuate other HPIV3 vaccine candi-
ate viruses. The F164S mutation also demonstrates that
e can import mutations from other related animal vi-
uses, such as SeV, that are attenuating in HPIV3. This
rovides us with an enlarged repertoire of mutations that
ight be useful in the production of human parainfluenza
accine candidates. Not only do the HPIV3 C, D, and V
utations appear to be promising for use in vaccine
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327C, D, AND V ORF MUTATIONS OF HPIV3evelopment, but also they have provided some insight
nto the role these proteins play in viral replication and
athogenesis.
MATERIALS AND METHODS
ells and viruses
HEp-2 and simian LLC-MK2 monolayer cell cultures
ere maintained in OptiMEM 1 (Life Technologies,
aithersburg, MD) supplemented with 2% FBS, gentami-
in sulfate (50 mg/ml), and 4 mM glutamine. The MVA
ecombinant virus that expresses bacteriophage T7 RNA
olymerase was generously provided by Drs. L. Wyatt
nd B. Moss (Wyatt et al., 1995). The JS WT strain of PIV3
nd its attenuated ts derivative, JS cp45, were propa-
ated in LLC-MK2 cells as described previously (Hall et
l., 1992).
DNAs
The full-length cDNA clone encoding the complete 15462
t antigenome [p3/7(131)2G] of the JS WT virus was de-
cribed previously (GenBank Accession no. Z11575)
Durbin et al., 1997a). This clone was used as the template
or the construction of five mutated cDNAs, one in which the
xpression of the C ORF was completely abrogated, a
econd that encodes a phenylalanine-to-serine change at
mino acid position 164 of the C ORF, a third and fourth in
hich expression of the D and V reading frames was
bolished individually, and a fifth in which the D and V
eading frame mutations were combined (Table 1, Fig. 1).
he PmlI-to-BamHI fragment of p3/7(131)2G (nt 1215–3903
f the PIV3 antigenome) was subcloned into the plasmid
UC119 [pUC119(PmlI–BamHI)], which had been modified
o include a PmlI site in the multiple cloning region. Site-
irected mutagenesis was then performed on
UC119(PmlI–BamHI) using the method of Kunkel et al.
1987) to introduce mutations in the C, D, and V ORFs,
hich are described immediately below.
Construction of antigenomic cDNA encoding the C
nockout mutant (rC-KO). Two primers were used to
ntroduce mutations that would silence expression of the
ORF (Table 1, Fig. 1C). The first mutagenic primer
hanged the C ORF start codon from ATG to ACG (me-
hionine to threonine) by altering nt position 1795 (T to C)
f the full-length antigenome and changed amino acid
osition 7 of the C ORF from serine to a stop codon by
ltering nt position 1813 (C to A). The second mutagenic
rimer replaced the serine at amino acid position 26 of
he C ORF with a stop codon by changing nt position
869 from C to A. These mutations introduced into the C
RF were silent in the P ORF.
Construction of antigenomic cDNA encoding virus with
he F164S mutation in the C ORF (rF164S). A phenylala-
ine (F)-to-serine (S) change at amino acid position 164
f the C ORF was created using a mutagenic primer that pntroduced an A-to-G change at nt position 2284 of the
ull-length antigenome (Table 1, Figs. 1C and 2). This
utation was also silent in the P ORF.
Construction of antigenomic cDNAs encoding the D, V,
nd DV knockout mutants (rD-KO, rV-KO, and rDV-KO).
utations were introduced that would interrupt expres-
ion of both the D and V ORFs individually. The D knock-
ut primer introduced C-to-A changes at nt positions
692, 2695, and 2698 of the full-length antigenome (Table
, Fig. 1). These point mutations created three succes-
ive stop codons in the putative D ORF that result in
remature termination of the D protein following codon
03 within the 372-amino acid chimeric D protein shown
n Fig. 1C. We were unable to introduce these stop
odons any earlier in the D ORF without causing a
oncomitant coding change in the P ORF; therefore,
xpression of the mutated ORF is not completely abro-
ated but would produce a truncated D protein contain-
ng the N-terminal 241 amino acids of P fused to 62,
ather than 131, amino acids of the D domain. The V
nockout mutagenic primer introduced two point muta-
ions at nt positions 2845 (A to T) and 2854 (C to T) of the
ull-length antigenome (Table 1). These mutations cre-
ted stop codons early (amino acids positions 17 and 20)
n the putative V ORF. These mutations were silent in the
ORF but introduced two amino acid substitutions in the
protein, namely Q354L and A357V. Both primers were
sed together in a single mutagenesis reaction to create
he combined DV knockout mutations.
The PmlI-to-BamHI fragment of each full-length clone
as sequenced in its entirety to confirm the presence of
he introduced mutations and to confirm that other mu-
ations had not been introduced incidentally. These frag-
ents were then separately cloned back into the full-
ength clone p3/7(131)2G as previously described
Durbin et al., 1997a) to create the five different antige-
omic cDNA clones.
ecovery of recombinant C knockout (rC-KO), C
164S (rF164S), D knockout (rD-KO), V knockout (rV-
O), and DV knockout (rDV-KO) mutants from cDNA
The full-length antigenomic cDNAs bearing either the
knockout mutations, the F164S mutation, or the DV
nockout mutations were transfected into HEp-2 cells on
-well plates (Costar, Cambridge, MA) together with the
upport plasmids [pTM (N), pTM (P no C), and pTM (L)]
sing LipofectACE (Life Technologies) and were infected
ith MVA-T7 as previously described (Durbin et al.,
997a). pTM (P no C) is identical to the pTM (P) plasmid
escribed previously (Durbin et al., 1997b) with the ex-
eption that the C transcriptional start site had been
utated from ATG to ACG, changing the first amino acid
n the C ORF from methionine to threonine. After incuba-
ion at 32°C for 3 days, the transfection harvest was
assaged onto a fresh LLC-MK2 cell monolayer in a T25
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328 DURBIN ET AL.lask and incubated for 5 days at 32°C (referred to as
assage 1). The amount of virus present in the F164S, D,
, and DV knockout passage 1 harvests was determined
y plaque titration on LLC-MK2 monolayer cultures with
laques visualized by immunoperoxidase staining with
IV3 HN-specific monoclonal antibodies as described
reviously (Durbin et al., 1997a). The C knockout virus
ppeared to grow poorly, so its passage 1 harvest was
urther amplified by a second passage in a monolayer of
LC-MK2 cells in a T75 flask. The amount of virus
resent in the passage 2 harvest was determined as
escribed above.
The F164S, D, V, and DV knockout viruses present in
he supernatants of passage 1 harvest were then plaque
urified three times on LLC-MK2 cells as previously
escribed (Hall et al., 1992). The C knockout virus could
ot be biologically cloned by plaque purification because
t was unable to form readily identifiable plaques; there-
ore, it was terminally diluted using twofold dilutions on
6-well plates (12 wells per dilution) of LLC-MK2 cells.
he biologically cloned recombinant viruses from the
hird round of plaque purification or terminal dilution
ere then amplified twice in LLC-MK2 cells at 32°C to
roduce virus for further characterization.
equence analysis of recovered recombinant viruses
Virus was concentrated from clarified medium from in-
ected cell monolayers through polyethylene glycol precip-
tation as described previously (Durbin et al., 1997a). The
NA was purified with TRIzol reagent (Life Technologies)
ollowing the manufacturer’s recommended procedure. RT-
CR was performed with the Advantage RT-for-PCR kit
Clontech, Palo Alto, CA) following the recommended pro-
ocol. Control reactions were identical except that reverse
ranscriptase was omitted from the reaction to confirm that
he PCR products were derived solely from viral RNA and
ot from possible contaminating cDNA plasmids. Primers
ere used to generate the PCR fragment spanning nt 1595–
104 of the full-length antigenome. This fragment includes
he entire C, D, and V ORFs of the recombinant viruses. The
esultant PCR products were then sequenced using cycle
ideoxynucleotide sequence analysis (New England Bio-
abs, Beverly, MA).
rotein analysis by immunoprecipitation
Two PIV3 C-specific antisera were raised in rabbits by
he multiple antigen peptide technique against two dif-
erent C peptides (Research Genetics, Huntsville, AL).
he two peptides spanned amino acid regions 30–44
nd 60–74 of the C protein. Eight copies of each C
eptide were placed on a branched carrier core and
njected separately into rabbits (two rabbits per peptide)
ith Freund’s adjuvant. The rabbits were boosted with
he designated multiple antigen peptide at 2 and 4
eeks and bled at 4, 8, and 10 weeks. Each antiserum cecognized the C peptide used as an immunogen in high
iter and precipitated C protein from HPIV3-infected cells
n an RIPA. Similarly, we attempted to produce antisera
gainst the D and V proteins but were unsuccessful; the
ntisera raised was of low titer against the peptide itself,
nd we were unable to detect the D or V proteins puta-
ively produced by cells infected with WT virus.
T25 cell monolayers of LLC-MK2 cells were infected at
n m.o.i. of 5 with either rC-KO, rF164S, or recombinant JS
T virus (rJS) or were mock infected and incubated at
2°C. At 24 h postinfection, the monolayer was washed
ith methionine-minus DMEM (Life Technologies) and
ncubated in the presence of 10 mCi/ml 35S methionine in
ethionine-minus DMEM for an additional 6 h. The cells
ere then harvested, washed three times, and resus-
ended in 1 ml of RIPA buffer containing 1% (w/v) sodium
eoxycholate, 1% (v/v) Triton X-100, 0.2% (w/v) SDS, 150
M NaCl, and 50 mM Tris–HCl, pH 7.4; freeze-thawed;
nd pelleted at 6500 g. The cell extract was transferred
o a fresh Eppendorf tube and a mixture of both C
ntisera (5 ml each) was added to each sample and
ncubated with constant mixing for 2 h at 4°C. Then 10 ml
f a mixture of monoclonal antibodies 454/11 and 101/1,
hich recognize the HN glycoprotein of HPIV3 (van Wyke
oelingh et al., 1987), were added to each sample to
onfirm that recovered virus was indeed HPIV3. Immune
omplexes were precipitated by the addition of 200 ml of
10% suspension of protein A-Sepharose beads (Sigma
hemical Co., St. Louis, MO) to each sample, followed by
onstant mixing at 4°C overnight. Each sample was
enatured, reduced, and analyzed on a 4–12% polyacryl-
mide gel (NuPAGE; Novex, San Diego, CA) according to
he manufacturer’s recommendations. The gel was dried
nd analyzed by autoradiography.
ulticycle replication of rPIV3s
Monolayers of LLC-MK2 cells in T25 flasks were in-
ected in duplicate with rC-KO, rF164S, rDV-KO, or rJS at
n m.o.i. of 0.01 and incubated at 32°C in 5% CO2. Then
50-ml samples were removed from each flask at 24-h
ntervals for 7 consecutive days and were flash frozen.
n equivalent volume of fresh media was replaced at
ach time point. Each sample was titered on LLC-MK2
ell monolayers in 96-well plates incubated for 7 days at
2°C. Virus was detected by hemadsorption and re-
orted as log10TCID50/ml.
nimal studies
The 4- to 6-week-old golden Syrian hamsters in groups
f 21 were inoculated intranasally with 0.1 ml/animal of
MEM (Life Technologies) containing 105 PFU of either
C-KO, rF164S, rDV-KO, rJS, cp45 (the biologically derived
ive attenuated derivative of JS WT virus), or RSV. On days
–5 postinoculation, five hamsters from each group, ex-
ept those which received RSV, were sacrificed, and the
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329C, D, AND V ORF MUTATIONS OF HPIV3ungs and nasal turbinates were harvested. The nasal
urbinates and lungs were homogenized to prepare a
0% or 20% w/v suspension in L-15 (Quality Biologicals,
aithersburg, MD), respectively, and the samples were
apidly frozen. Virus present in the samples was titered
n 96-well plates of LLC-MK2 cell monolayers incubated
t 32°C for 7 days. Virus was detected by hemadsorp-
ion, and the mean log10TCID50/g was calculated for each
ay for each group of five hamsters. Sera were collected
rom the remaining six hamsters in each group on days
and 28 postinoculation. Serum antibody responses to
ach virus were evaluated by HAI assay as previously
escribed (van Wyke Coelingh et al., 1985). On day 28,
he remaining hamsters in each group, including those
mmunized with RSV, were challenged intranasally with
06 PFU of biologically derived PIV3 JS WT virus. The
nimals were sacrificed on day 4 postchallenge, and the
ungs and nasal turbinates were harvested and pro-
essed as described above. The quantity of virus present
n the challenge samples was determined as described
bove. A separate study was performed in which rD-KO
nd rV-KO were administered to hamsters as described
bove except that the animals were not challenged.
AGMs in groups of four animals each were inoculated
ntranasally and intratracheally with 106 PFU of either
C-KO, rF164S, rDV-KO, JS WT, or cp45 as previously
escribed for earlier studies in rhesus monkeys (Durbin
t al., 1998). Nasopharyngeal swab samples were col-
ected daily for 12 consecutive days postinoculation, and
racheal lavage samples were collected on days 2, 4, 6,
, and 10 postinoculation. The specimens were flash
rozen and stored at 270°C until all specimens had been
ollected. Virus present in the samples was titered on
LC-MK2 cell monolayers in 96-well plates that were
ncubated at 32°C for 7 days. Virus was detected via
emadsorption, and the mean log10TCID50/ml was calcu-
ated for each day. Serum was collected from each mon-
ey on days 0 and 28, and the PIV3 HAI antibody re-
ponse to experimental infection with the various mu-
ants and the PIV3 WT (JS) was determined. On day 28
ostinoculation, the AGMs were challenged with 106 PFU
f the biologically derived PIV3 WT virus administered in
1-ml inoculum intranasally and intratracheally. Naso-
haryngeal swab samples were collected on days 0, 1, 2,
, 6, 8, 10, and 12 postchallenge, and tracheal lavage
amples were collected on days 2, 4, 6, 8, and 10 post-
hallenge. Specimens were flash frozen and stored, and
irus present was titered as described above. Virus from
he tracheal lavage day 8 and nasopharyngeal swab day
specimens from AGMs that had received rF164S was
mplified in LLC-MK2 cells. The viral RNA was then
solated and sequenced as described above to deter-
ine whether the F164S mutation remained intact after
eplication in vivo. This sequencing technique detects a
onsensus sequence and is not suitable for detectingow levels of revertant or modified virus. GACKNOWLEDGMENTS
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